- Cognitive engagement may slow clinical progression and brain atrophy in Huntington's disease
- New therapy for Huntington's disease 'may slow disease progression' | Shropshire Star
- New therapy for Huntington's disease 'may slow disease progression' - Ireland Live
- With Trump on the way, advocates look to states to pick up medical debt fight
- New therapy for Huntington's disease 'may slow disease progression' | The Independent
- Common heart drug shows promise for Huntington's disease - DT Next
- Intra-Cellular Eyes Depression Approval for Caplyta as Stock Flies Under the Radar
- Joshua Burgess Obituary (2024) - Allen, TX - Legacy.com
- Common heart drug shows promise for Huntington's disease - INDIA New England News
- PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy | Nasdaq
- Obituary information for John W. Kenney - Chapman Funerals...
- Common heart drug shows promise for Huntington's disease - tennews.in
- Common heart drug shows promise for Huntington's disease | News Room Odisha
- Early Dementia Predictors; Neural Data Privacy; An Artist's Journey Into Parkinson's
- PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy - TradingView
- Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion - Yahoo Finance
- Novartis Secures Deal For PTC's Huntington's Disease Drug - The Pinnacle Gazette
- Heart Drug Offers New Hope For Huntington's Disease - The Pinnacle Gazette
- Takeda, Novartis, and Gilead Strike Separate Licensing Deals - Pharmaceutical Executive
- Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion - December 3, 2024
- UK's NICE Reverses Course on Immunocore's Kimmtrak for Advanced Uveal Melanoma
- 'Anyone would': mother vows to fight for her son's final stages of life - Daily Liberal
- Sarepta to buy Arrowhead's muscular dystrophy treatment programs
- ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…
- Novartis Pens $2.9B Deal With PTC Therapeutics for Huntington's Disease Drug
- PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's ... - MSN
- Novartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntington's disease
- Giving Thanks to the Huntington's Disease Family Community for Advancing Research
- Gilead Plots ADC Comeback with Potential $465M License Agreement - BioSpace
- Maryland's cannabis-related emergency room visits are trending downward since legalization
- Sarepta gains rights to Arrowhead Huntington's treatment candidate
- Study suggests heart medication can slow Huntington's disease progression - indica News
- COUR Pharmaceuticals Enters Collaboration and Licensing Agreement with Genentech to ...
- Novartis gains rights to PTC's Huntington's programme in deal worth up to $2.9bn - PMLiVE
- Exclusive: Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms
- PTC Therapeutics (PTCT) PT Raised to $42 at Goldman Sachs - StreetInsider
- Apogee Therapeutics Advances in I&I Disease Treatments - Yahoo Finance
- Applied Therapeutics says it received FDA's warning letter for genetic disease drug study
- Novartis to advance novel Huntington's disease therapy - European Pharmaceutical Review
- PTC upgraded to outperform by RBC on Novartis deal - MSN
- Novartis in up to $2.9 billion licensing deal for PTC Therapeutics Huntington's disease drug
- PTC Therapeutics boosted by Novartis rights deal for Huntington's program
- Novartis and PTC Therapeutics link to develop Huntington's therapy - Yahoo Finance
- Common heart drug shows promise for Huntington's disease - Punjab News Express
- mRNA splicing modifier - BioWorld
- Kentucky medical cannabis certifications begin Dec. 1 - WPSD Local 6
- common heart drug shows promise for huntingtons disease | tripuratimes
- Novartis paying $1B up front to PTC in Huntington's pact | BioWorld
- Novartis and PTC partner for Huntington's disease therapy - Pharmaceutical Technology
- Novartis taps PTC for it Huntington's disease therapy PTC518
RSS Feed – News
HDinHD > RSS Feed – News
